Overview Dividends

(MYGN) Myriad Genetics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US62855J1043

Hereditary Cancer, Companion Diagnostic, Prognostic Tumor, Prenatal Screening, Pharmacogenomic Mental

MYGN EPS (Earnings per Share)

EPS Growth (3Y CAGR): -72.79%
EPS Trend (3Y Correlation): 13.8%

MYGN Revenue

Revenue Growth (3Y CAGR): 11.91%
Revenue Trend (3Y Correlation): 86.4%

Risk via 10d forecast
Volatility	74.8%
Value at Risk 5%th	104%

Reward
Sharpe Ratio	-0.70
Alpha	-87.90

Character
Hurst Exponent	0.335
Beta	1.812

Drawdowns 3y
Max DD	86.57%
Mean DD	31.75%

Description: MYGN Myriad Genetics October 24, 2025

Myriad Genetics (NASDAQ: MYGN) is a U.S.-based molecular diagnostics firm that commercializes DNA- and RNA-based tests across oncology, women’s health, pharmacogenomics, and mental-health indications. Its flagship offerings include the MyRisk hereditary-cancer panel, BRACAnalysis CDx and MyChoice CDx companion diagnostics for BRCA-related cancers, Prolaris and EndoPredict prognostic assays, as well as prenatal screens such as Prequel and Foresight Carrier, and the GeneSight psychotropic-medication test.

In FY 2023 the company reported revenue of roughly $1.1 billion, a 5 % year-over-year increase driven primarily by higher test volumes in its oncology and prenatal segments; the gross margin held steady near 80 %, while operating cash flow turned positive for the first time in three years, reflecting improved reimbursement capture and cost-discipline.

Key growth drivers for Myriad include the expanding market for precision oncology-projected to exceed $30 billion by 2028-accelerating adoption of companion diagnostics tied to FDA-approved targeted therapies, and demographic trends (aging population and rising cancer incidence) that boost demand for hereditary-cancer screening. Conversely, the business faces pricing pressure from emerging NGS platforms and regulatory uncertainty around coverage policies for multi-gene panels.

For a deeper, data-driven assessment of MYGN’s valuation and risk profile, you may find the analytical tools on ValueRay useful for independent research.

MYGN Stock Overview

Market Cap in USD	587m
Sub-Industry	Biotechnology
IPO / Inception	1995-10-05
Return 12m vs S&P 500	-66.6%
Analyst Rating	3.33 of 5

MYGN Dividends

Currently no dividends paid

MYGN Growth Ratios

CAGR	-31.85%
CAGR/Max DD Calmar Ratio	-0.37
CAGR/Mean DD Pain Ratio	-1.00
Current Volume	967.9k
Average Volume	963.8k

Piotroski VR‑10 (Strict, 0-10) 3.5

Net Income (-395.2m TTM) > 0 and > 6% of Revenue (6% = 50.0m TTM)

FCFTA -0.07 (>2.0%) and ΔFCFTA 5.64pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 10.13% (prev 17.79%; Δ -7.66pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA -0.03 (>3.0%) and CFO -22.6m > Net Income -395.2m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 1.42 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (92.5m) change vs 12m ago 2.10% (target <= -2.0% for YES)

Gross Margin 70.44% (prev 69.06%; Δ 1.38pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 94.52% (prev 73.93%; Δ 20.59pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -109.6 (EBITDA TTM -357.6m / Interest Expense TTM 3.80m) >= 6 (WARN >= 3)

Altman Z'' -11.54

(A) 0.12 = (Total Current Assets 284.3m - Total Current Liabilities 199.9m) / Total Assets 677.3m

(B) -1.61 = Retained Earnings (Balance) -1.09b / Total Assets 677.3m

warn (B) unusual magnitude: -1.61 — check mapping/units

(D) -3.76 = Book Value of Equity -1.09b / Total Liabilities 289.2m

Total Rating: -11.54 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 34.60

1. Piotroski 3.50pt = -1.50

2. FCF Yield -7.49% = -3.75

3. FCF Margin -6.00% = -2.25

4. Debt/Equity 0.40 = 2.42

5. Debt/Ebitda -0.22 = -2.50

6. ROIC - WACC (= -71.41)% = -12.50

7. RoE -62.59% = -2.50

8. Rev. Trend 86.43% = 6.48

9. EPS Trend 13.77% = 0.69

What is the price of MYGN shares?

As of November 12, 2025, the stock is trading at USD 6.68 with a total of 967,915 shares traded.
Over the past week, the price has changed by +3.41%, over one month by -14.80%, over three months by +7.92% and over the past year by -61.41%.

Is Myriad Genetics a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Myriad Genetics (NASDAQ:MYGN) is currently (November 2025) a stock to sell. It has a ValueRay Fundamental Rating of 34.60 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of MYGN is around 4.72 USD . This means that MYGN is currently overvalued and has a potential downside of -29.34%.

Is MYGN a buy, sell or hold?

Myriad Genetics has received a consensus analysts rating of 3.33. Therefor, it is recommend to hold MYGN.

Strong Buy: 3
Buy: 3
Hold: 6
Sell: 2
Strong Sell: 1

What are the forecasts/targets for the MYGN price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	8.3	24.1%
Analysts Target Price	8.3	24.1%
ValueRay Target Price	5.4	-19.9%

MYGN Fundamental Data Overview November 11, 2025

Market Cap USD = 587.2m (587.2m USD * 1.0 USD.USD)
P/E Forward = 54.0541
P/S = 0.7116
P/B = 1.8125
P/EG = 1.4001
Beta = 1.812
Revenue TTM = 832.9m USD
EBIT TTM = -416.5m USD
EBITDA TTM = -357.6m USD
Long Term Debt = 39.6m USD (from longTermDebt, last fiscal year)
Short Term Debt = 68.4m USD (from shortTermDebt, last quarter)
Debt = 154.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 80.2m USD (from netDebt column, last quarter)
Enterprise Value = 667.4m USD (587.2m + Debt 154.6m - CCE 74.4m)
Interest Coverage Ratio = -109.6 (Ebit TTM -416.5m / Interest Expense TTM 3.80m)
FCF Yield = -7.49% (FCF TTM -50.0m / Enterprise Value 667.4m)
FCF Margin = -6.00% (FCF TTM -50.0m / Revenue TTM 832.9m)
Net Margin = -47.45% (Net Income TTM -395.2m / Revenue TTM 832.9m)
Gross Margin = 70.44% ((Revenue TTM 832.9m - Cost of Revenue TTM 246.2m) / Revenue TTM)
Gross Margin QoQ = 71.23% (prev 68.50%)
Tobins Q-Ratio = 0.99 (Enterprise Value 667.4m / Total Assets 677.3m)
Interest Expense / Debt = 0.97% (Interest Expense 1.50m / Debt 154.6m)
Taxrate = 0.03% (-100.0k / -330.6m)
NOPAT = -416.4m (EBIT -416.5m * (1 - 0.03%)) [loss with tax shield]
Current Ratio = 1.42 (Total Current Assets 284.3m / Total Current Liabilities 199.9m)
Debt / Equity = 0.40 (Debt 154.6m / totalStockholderEquity, last quarter 388.1m)
Debt / EBITDA = -0.22 (negative EBITDA) (Net Debt 80.2m / EBITDA -357.6m)
Debt / FCF = -1.60 (negative FCF - burning cash) (Net Debt 80.2m / FCF TTM -50.0m)
Total Stockholder Equity = 631.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -58.35% (Net Income -395.2m / Total Assets 677.3m)
RoE = -62.59% (Net Income TTM -395.2m / Total Stockholder Equity 631.5m)
RoCE = -62.07% (EBIT -416.5m / Capital Employed (Equity 631.5m + L.T.Debt 39.6m))
RoIC = -61.16% (negative operating profit) (NOPAT -416.4m / Invested Capital 680.8m)
WACC = 10.25% (E(587.2m)/V(741.8m) * Re(12.69%) + D(154.6m)/V(741.8m) * Rd(0.97%) * (1-Tc(0.00)))
Discount Rate = 12.69% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.65%
Fair Price DCF = unknown (Cash Flow -50.0m)
EPS Correlation: 13.77 | EPS CAGR: -72.79% | SUE: -4.0 | # QB: 0
Revenue Correlation: 86.43 | Revenue CAGR: 11.91% | SUE: 1.81 | # QB: 1

Additional Sources for MYGN Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle